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Pathogenic Variants in Fucokinase Cause a
Congenital Disorder of Glycosylation
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Undiagnosed Diseases Network, William J. Craigen,2 David R. Bearden,5 Brett H. Graham,2,6
and Hudson H. Freeze1,*
FUK encodes fucokinase, the only enzyme capable of converting L-fucose to fucose-1-phosphate, which will ultimately be used for syn-
thesizing GDP-fucose, the donor substrate for all fucosyltransferases. Although it is essential for fucose salvage, this pathway is thought
to make only a minor contribution to the total amount of GDP-fucose. A second pathway, the major de novo pathway, involves conver-
sion of GDP-mannose to GDP-fucose. Here we describe two unrelated individuals who have pathogenic variants in FUK and who
presented with severe developmental delays, encephalopathy, intractable seizures, and hypotonia. The first individual was compound
heterozygous for c.667T>C (p.Ser223Pro) and c.2047C>T (p.Arg683Cys), and the second individual was homozygous for c.2980A>C
(p.Lys994Gln). Skin fibroblasts from the first individual confirmed the variants as loss of function and showed significant decreases
in total GDP-[3H] fucose and [3H] fucose-1-phosphate. There was also a decrease in the incorporation of [5,6-3H]-fucose into fucosylated
glycoproteins. Lys994 has previously been shown to be an important site for ubiquitin conjugation. Here, we show that loss-of-function
variants in FUK cause a congenital glycosylation disorder characterized by a defective fucose-salvage pathway.Congenital disorders of glycosylation (CDG) are a group of
clinically heterogenous disorders resulting from abnormal
protein or lipid glycosylation.1–3 Genetic defects altering
N-linked glycosylation account for the majority of the
nearly 130 distinct glycosylation disorders; however,
exome sequencing has uncovered many disorders
involving the glycosylphosphatidylinositol (GPI) anchor
and the glycosaminoglycan (GAG), O-linked, and glyco-
lipid pathways.3,4
A common formof glycosylation termed fucosylation in-
volves incorporating the monosaccharide L-fucose (also
known as 6-deoxy-L-galactose) into many glycans.5 It re-
quires both the generation of the donor substrate guano-
sine diphosphate L-fucose (GDP-fucose) and the presence
of a set of fucosyltransferases that transfer L-fucose to the
specific glycan.5 In mammals, GDP-fucose is generated via
two distinct mechanisms, a de novo pathway and a salvage
pathway5 (Figure 1A). The de novo pathway utilizes a multi-
step reaction that converts GDP-mannose to GDP-fucose
and requires both GDP-mannose 4,6-dehydratase (GMDS)
and GDP-keto-6-deoxymannose 3,5 epimerase (TSTA3)
(aka FX protein). The de novo pathway relies heavily on
the cell’s ability to convert glucose and mannose to GDP-
mannose and ultimately GDP-fucose (Figure 1A).5–7 Loss
of either GMDS (MIM: 602884) or TSTA3 (MIM: 137020)
by genetic manipulation or chemical inhibitors results in
a near-complete loss of all cellular fucosylation.8–10
The salvage pathway uses b-L-fucose provided by two
routes. The first route is through the transport of exoge-
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inside the cell. Fucokinase (FUK) phosphorylates b-L-
fucose to generate b-L-fucose-1-phosphate (b-L-Fuc1p),
which subsequently undergoes a fucose-1-phosphate gua-
nylyltransferase (FPGT)-dependent condensation reaction
with guanosine triphosphate (GTP) to form GDP-b-L-
fucose (Figure 1A).5,12
It is important to note that only the b-anomers of
L-fucose can be utilized by human cells, and when a fuco-
syltransferase (such as FUT8) utilizes GDP-b-L-fucose to
create a glycosidic linkage, an inversion that switches
b-L-fucose anomers to a-L-fucose occurs.5
This anomeric shift is critical because fucosylated-glycan
hydrolysis, which occurs exclusively within the lysosome,
is performed by the lysosomal a-fucosidases (FUCA1) and
liberates free a-L-fucose to be transported out of the lyso-
some and into the cytoplasm (Figure 1A).13,14 The final
step of the process is catalyzed by the fucose mutarotase
(FUOM), which carries out another anomeric reaction con-
verting a-L-fucose back to the biologically active b-L-
fucose.15 From now on, all reference to L-fucose will be
to b-L-fucose, unless otherwise specified.
Although the roles for fucosylation, particularly FUT8-
dependent core fucosylation, have been well documented
in immune regulation, cancer metastasis, and inflamma-
tion, the precise contributions of either the de novo or the
salvage pathways have not been extensively studied.16–21
However, recent studies have shed light on the importance
of the salvage pathway and the roles of GMDS, TSTA3, and
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Figure 1. Identification of FUK Pathogenic Variants in Two Unrelated Families
(A) Schematic depiction showing the fucose de novo (left) and salvage (right) pathways.
(B) Pedigrees showing FUK pathogenic variants and segregation in families for individual 1 (CDG-0440) and individual 2 (CDG-
9286647).
(C) A schematic depiction of human FUK highlights each pathogenic variant on mRNA (GenBank: NM_145059.2) and protein amount
(Uniprot: Q8N0W3).
(D) Alignment of several organisms and the conservation of the residue of each identified variant.of several forms of cancer, includingmelanoma, colorectal,
and hepatocellular carcinomas.22–25
To date, no genetic disorders have been specifically
identified within either the de novo or salvage pathways,
although pathogenic mutations have been identified in
several downstream components of the fucosylation
pathway. For example, recessive mutations in SLC35C1
(MIM: 605881) cause leukocyte adhesion deficiency
type II (LADII), also known as SLC35C1-CDG (MIM:
266265), and are due to an inability to transport
GDP-fucose into the Golgi.26,27 Recessive mutations in
the fucosyltransferase 8 (FUT8) (MIM: 602589) cause
FUT8-CDG (MIM: 618005), characterized as a severe,multi-
system disorder involving a defect in the most prevalent
type of fucosylation, core fucosylation.28 Finally, recessive
mutations in a-fucosidase 1 (FUCA1) (MIM: 612280) result
in an inability to hydrolyze fucose from fucosylated glyco-
proteins and glycolipids, and they cause the rare lyso-
somal-storage disorder fucosidosis (MIM: 230000).29
We detail two unrelated individuals who had profound
neurological impairments and who were found to have
variants of uncertain significance (VUS) in FUK (MIM:
608675); here, we show evidence for the variants’ pathoge-
nicity. Prior to the research studies, informed consent was
obtained as part of the Undiagnosed Diseases Network, ac-
cording to the institutional review board of the National
Human Genome Research Institute.The American JourIndividual 1 (CDG-0440) is a male born without com-
plications to healthy, non-consanguineous parents of
Hispanic origin. He has a history of feeding difficulties
secondary to hypotonia, dysphagia, and GI dysmotility.
He has reflux and is noted to have poor gastric emptying.
Consequently, he does not take food by mouth and has a
G-J tube placement for feedings (Table 1). He presents
with severe developmental delays and multiple neurolog-
ical complications, including severe intellectual disabil-
ities, hypotonia, and intractable seizures (Table 1). An
electroencephalogram (EEG) showed extremely abnormal
background activity consistent with severe diffuse distur-
bance in cerebral function: multifocal epileptiform
activity involving the hemispheres bilaterally and brief
multifocal seizures. This activity was interpreted as gener-
alized tonic-clonic-type seizures in the setting of epileptic
encephalopathy (Table 1). MRI findings showed a dys-
morphic corpus callosum, a supratentorial ventricular
system, and borderline macrocephaly in the presence of
generous extra-axial CSF spaces and delays in deep-
white-matter myelination (Table 1). He has had recurrent
respiratory infections and episodes of apnea, one of
which required lifesaving intervention. He is also noted
to have symmetric maculopathy with severe visual
impairment. Extensive laboratory studies have shown
an elevated CSF:plasma glycine ratio and a mild, yet
persistent elevation of homocysteine (18.2–22.3 mmol/Lnal of Human Genetics 103, 1030–1037, December 6, 2018 1031
Table 1. Molecular and Clinical Characterization of Two Individuals with Pathogenic Variants in FUK
Individual 1 (CDG0440) Individual 2 (CDG9286647)
Sex male female
Current age 6 years 7 years
Ancestry Hispanic Middle Eastern (Qatari)
Age at onset of symptoms 3 years 4 years
FUK pathogenic variants c.667T>C (p.Ser223Pro); c.2047C>T (p.Arg683Cys) c.2980A>C (p.Lys994Gln)
Pregnancy complications No born premature at 25 weeks (810 g)
Feeding problems Feeding difficulties were secondary to hypotonia,
dysphagia, and GI dysmotility. Positive for reflux
and is noted to have poor gastric emptying. Does
not take food by mouth and has a G-J tube
placement for feedings.
Feeding difficulties were categorized by aspiration
with oral feeds, necessitating G-tube feeding.
Noted for chronic malabsorption with diarrhea.
Facial features or dysmorphism no no
Developmental delay yes yes
Stature normal for age normal for age
Intellectual disability yes, severe yes, severe
Seizures/epilepsy multifocal epileptiform activity involving the
hemispheres bilaterally and brief multifocal
seizures, interpreted as generalized tonic-clonic
type seizures in the setting of epileptic
encephalopathy.
Seizures were initially consistent with infantile
spasms (flexor spasms), and EEG findings showed
hypsarrhythmia.
Ataxia or gait problems nonambulatory nonambulatory
Hypotonia central hypotonia central hypotonia with limb spasticity
Brain anomalies yes, dysplastic corpus callosum, delayed
myelination in deep white matter
yes, cerebellar atrophy, agenesis of corpus callosum,
white matter abnormalities that were characterized
as severe periventricular leukomalacia with paucity
of white matter
Ocular symmetric maculopathy with severe visual
impairment
Strabismus, nystagmus, cortical blindness, optic
nerve atrophy
Skeletal contractures contractures
Cardiac none none
Respiratory recurrent respiratory infections respiratory difficulties
Hepatopathy yes, elevated gamma glutamyl transferase (GGT) no
Gastrointestinal GI problems. G-J-tube, motility issues GI Problems. G-tube, history of neonatal necrotizing
enterocolitis with bowel perforation
Immunological recurrent infections, enlarged platelets no
Biochemical testing abnormalities normal carbohydrate-deficient transferrin result none reported[normal range 4–14 mmol/L]) and methylmalonic acid
(MMA) (0.94–1.2 nmol/L [normal range 0–0.5 nmol/L])
concentrations in the blood; these elevated amounts
decreased slightly in response to hydroxocobalamin sup-
plementation. Importantly, at three months of age and
prior to hydroxocobalamin treatment, the B12 measure-
ment was 1,353 pg/mL (normal is 211–911 pg/mL). The
concentrations of homocysteine and MMA did not
normalize when the individual was given B12, and thus
it is not a B12 deficiency that is causing the elevated
methylmalonic acid concentrations, but rather a problem
in the transport or activation of B12.
Whole-exome-sequencing was performed on trio
genomic DNA and did not identify any candidates that1032 The American Journal of Human Genetics 103, 1030–1037, Deccould explain the abnormal biochemical results. A de
novo VUS was identified in KMT2b (MIM: 606834)
c.644C>A (p.Thr215Asn); however, the variant was predi-
cated to be benign or tolerated, and the clinical phenotype
associated with KMT2B, autosomal-dominant Dystonia
28, childhood-onset (MIM: 617284), did not fit the presen-
tation of individual 1. WES did identify two VUSs in FUK
(GenBank: NM_145059.2), c.667T>C (p.Ser223Pro) and
c.2047C>T (p.Arg683Cys) (Figure 1B, Table 1).
Individual 2 (CDG-9286647) is a female born prema-
turely at 25 weeks to healthy, consanguineous parents of
Qatari origin. Like individual 1, she has a history of feeding
problems, respiratory difficulties, developmental delays,
severe intellectual disabilities, intractable seizures, andember 6, 2018
Figure 2. Immunoblot Analysis of FUK
Protein in Control and Individual 1 (CDG-
0440) Fibroblasts and Lymphoblasts
Upper panel: immunoblot analysis with a
monoclonal FUK antibody was used for
comparison of three controls and individ-
ual 1 and shows an 80% reduction in
FUK protein amount. Lower panel: immu-
noblot analysis of FUK in EBV-transformed
lymphoblasts from three controls, the par-
ents of individual 1 (1-1, father; 1-2,
mother), and individual 1 (2-1, proband).
The mAb to FUK (6E2) (Thermo Fisher
MA5-15847) was used at a 1:1000 dilution.hypotonia (Table 1). Her feeding difficulties were charac-
terized by aspiration with oral feeds, necessitating G-tube
feeding. She had chronic malabsorption with diarrhea,
although this was at least partly due to the fact that she
had a history of necrotizing enterocolitis and had had a
partial small-bowel resection (Table 1). She did present
with failure to thrive, but this was well managed early on
and has since improved. An MRI showed cerebellar atro-
phy, agenesis of the corpus callosum, and white-matter
abnormalities; these symptoms were all characterized as se-
vere periventricular leukomalacia with paucity of white
matter andwere more consistent with a destructive process
rather than delayed myelination or demyelination. Also
present were cystic encephalomalacia, as well as a small
pons and cerebellum that were initially read as consistent
with pontocerebellar hypoplasia (Table 1). Her seizures
were initially consistent with infantile spasms (flexor
spasms), and the EEG findings showed hypsarrhythmia.
After treatment for infantile spasms, seizures evolved and
were primarily characterized by eye blinking and brief
arrest in activity; EEGs continued to show variant hypsar-
rhythmia (continued disorganization typical of hypsar-
rhythmia but low voltage). Spasms were responsive to
treatment with prednisone, but eye-blinking seizures
were refractory to multiple medications (Table 1).
She also presented with ocular problems, including
strabismus, optic-nerve atrophy, and cortical blindness
(Table 1). Furthermore, she did not show the same abnormal
metabolic profile as individual 1.WESwas performed on trio
genomic DNA and identified a homozygous FUK VUS,
c.2980A>C (p.Lys994Gln) (Figure 1B, Table 1). Both individ-
uals have had their WES data reanalyzed and did not show
any additional variants of interest to prioritize.
In silico modeling using the Combined Anno-
tation Dependent Depletion (CADD) scoring method30
showed that all three FUK variants, c.667T>C
(p.Ser223Pro) (CADD ¼ 24.8), c.2047C>T (p.Arg683Cys)
( CADD ¼ 32), and c.2980A>C (p.Lys994Gln) (CADD ¼
28.1), were predicted to be in the top 0.5% of deleterious
variants.The American Journal of Human GeneticsWe used the Genome Aggregation
Database (gnomAD) of 123,136
exomes and 15,496 genomes (Ver2:accessed October 12, 2018) to highlight the rarity of these
three variants; we found the c.667T>C (p.Ser223Pro)
variant in 17 carriers from 246,034 alleles, the
c.2047C>T (p.Arg683Cys) variant in 27 carriers from
168,584 alleles, and the c.2980A>C (p.Lys994Gln) variant
in 65 carriers from 276,772 alleles. Importantly, we did not
identify any homozygotes for any of the three variants.
Given the rarity of these three variants and the fact that
they are predicted to be deleterious, we focused on FUK
as a plausible candidate for biochemical investigation.
Fucokinase shares protein homology with other kinases
within the highly conserved GHMP kinase superfamily,
which includes galactokinase (GALK) and the plant-spe-
cific L-arabinokinase (ARA1). Like FUK, GALK and ARA1
are both sugar-1 phosphate-generating kinases.31 The
p.Ser223Pro variant occurs in the L-fucokinase domain,
but the p.Arg683Cys variant occurs between the L-fucoki-
nase domain and the GHMP kinase N-terminal domain,
where the ATP binding motif resides (Figure 1C). The
p.Lys994Gln variant occurs within the GHMP kinase C-ter-
minal domain (Figure 1C). All three amino acids are highly
conserved within higher eukaryotes (Figure 1D), which is
reflected in the previously mentioned CADD scores.
For individual 1, bothprimaryfibroblast and transformed
lymphoblast cell lines were available for biochemical anal-
ysis. Unfortunately, neither was available for individual 2.
Immunoblot analysis with a monoclonal FUK antibody
(Thermo Fisher MA5-15847) showed that fibroblasts from
individual 1 had an 80% reduction in the amount of
FUK antigen when they were compared to three commer-
cially available control fibroblast cultures (Figure 2).
Furthermore, lymphoblasts derived from this individual
also showed a clear reduction (60%) in the amount of
FUK antigens, although to a lesser extent than in the fibro-
blasts (Figure 2). All FUK immunoblots were normalized to
alpha tubulin levels (Figure 2).
We used two independent methods to directly assay FUK
activity in fibroblasts from individual 1. The first method
measured how much [5,6-3H]-fucose had been incorpo-
rated into cell-associated glycoproteins (i.e., fucosylated103, 1030–1037, December 6, 2018 1033
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Figure 3. Determination of FUK Activity in Control and Individual 1 (CDG-0440) Fibroblasts
(A) Metabolic labeling of fibroblasts (3 controls and individual 1 all in triplicate) with 2 mCi/mL [5,6-3H]-fucose for 24 hr and determi-
nation of [3H]-fucose incorporation into cell-associated protein. After the cells were normalized to protein content, individual 1 had a
70% reduction in fucose incorporation when this individual was compared to the three controls.
(B) In vitro FUK assay performed with crude cytoplasmic extracts and [5,6-3H]-fucose as the substrate. After the kinase reaction, the prod-
uct [5,6-3H] fucose-1-phosphate was purified via ion-exchange chromatography and counted with a scintillation counter.
The assay was performed in three biological replicates with error bars representing standard deviations.glycoproteins). Normally, cultured cells are not grownwith
exogenous L-fucose, except for that present in the supple-
mented bovine/calf serum. Any exogenously provided
L-fucose will be utilized by the salvage pathway and incor-
porated into fucosylated glycoproteins via the previously
mentioned salvage pathway. Therefore, providing exoge-
nous [5,6-3H]-fucose and observing its incorporation
should be a direct measure of FUK activity. When
compared to the average of three controls, the amount of
[5,6-3H]-fucose incorporated into cell-associated fucosy-
lated glycoproteins in individual 1 was 70% lower
(Figure 3A). Furthermore, we determined a 60% reduction
in both GDP-[3H] fucose and [3H]-Fuc1p (Figure S1A). Both
of these results are consistent with a loss of FUK activity.
Importantly, lentiviral transduction of wild-type FUK
into fibroblasts from individual 1 was able to restore
[5,6-3H]-fucose incorporation (Figure S1B and S1C).
The second method is an in vitro assay of FUK kinase ac-
tivity. Unlike the previous method, which involved radio-
labeling live cells, the in vitro method required growing
substantial amounts of cells to prepare crude cytoplasmic
cell extracts in which to assay FUK activity.32,33 After lysis,
FUK activity decreases rapidly due to enzyme insta-
bility.32,33 After optimizing assay conditions for primary
control fibroblasts, we found that individual 1 had nearly
no FUK activity, in contrast to the higher activity in two
control cell lines (Figure 3B). Although these results sup-
port individual 1’s having no FUK activity, we know there
is residual FUK activity from the cell-based [5,6-3H]-fucose
labeling experiments. These results can be explained in
part by the inherent instability of wild-type FUK once
the cells are lysed and by the further instability that indi-
vidual 1 has as a result of FUK variants.
Because there is no other known fucose kinase, both the
cell-based and in vitro assays can be seen as direct measure-
ments of FUK activity. To confirm this assumption, we1034 The American Journal of Human Genetics 103, 1030–1037, Deccreated a CRISPR/Cas9 FUK knockout (KO) HAP1 cell line
and showed that when we provided exogenous [5,6-3H]-
fucose, there was no incorporation into either cell-associ-
ated fucosylated glycoproteins or purified soluble fractions
where GDP-fucose or fucose-1p would be present; thus, we
proved there is no other kinase capable of substituting for
FUK (Figure S2A).
Because the vast majority of GDP-fucose is generated via
the de novo pathway, we hypothesized that the loss of the
salvage pathway would have minimal effects on total
cellular fucosylation. Flow-cytometric analysis of both fi-
broblasts from individual 1 and FUK KO cells supported
this hypothesis and showed no detectable changes in
fucose-dependent lectin binding (data not shown).
Furthermore, mass-spectrometry analysis of total serum
N- and O-glycans from individual 1 showed no obvious
changes in either total or individual N-glycan composition
(data not shown). These results support the notion that the
salvage pathway might be more critical in some cell types
but that others can function without it.
Unfortunately, no cell lines from individual 2 were avail-
able to assay. Attempts to use lentiviral complementation
of our FUK knockout (KO) HAP1 cells highlighted that
FUK protein level is highly regulated and likely cell type-
dependent. For example, in fibroblasts from individual 1,
we consistently saw an 80% reduction in FUK protein
amount with the corresponding reduction in [5,6-3H]-
fucose incorporation into cell-associated material (Figures
2 and 3A). However, when we used lentivirus to infect
the FUK KO cells with either FUK variant from individual
1, individually or in combination, the protein amounts
of either variant were comparable to those of wild-type
cells (data not shown). This suggests either that FUK pro-
tein amount is highly regulated and varies among different
cell types or that perhaps the lentiviral promoter used was
producing too much FUK protein. We addressed the latterember 6, 2018
possibility by infecting the FUK KO cells with lentiviral
constructs containing both a weak EF1 and strong
CMV promoter and obtained similar outcomes (data not
shown).
Despite being unable to create a usable cell-based model
to assay the p.Lys994Gln variant from individual 2, we
identified published proteomic studies highlighting
Lys994 as an important site of ubiquitin conjugation in
both mouse and human tissue samples.34,35 Because we
cannot perform cell-based assays to confirm the pathoge-
nicity of the p.Lys994Gln found in individual 2, we are
classifying it as a likely pathogenic variant.
The primary function of FUK as the only known fucose-
1-phosphate kinase across nearly all species is well estab-
lished. However, the biological consequence of losing
FUK or the fucose salvage pathway is not well understood.
To date, no Fuk- or Fpgt-knockout (KO) mouse models are
available, but studies using Tsta3 KO mice have shown
how critical the de novo pathway is to both animal sur-
vival and total cellular fucosylation.9 In fact, HAP1 cells
null for FUK do not show a clear fucosylation defect as
determined by lectin staining (data not shown). Clearly,
the de novo pathway provides adequate levels of GDP-
fucose needed to carry out fucosylation in this cell line,
and this most likely holds true for other cell types as
well. Cancer cells lacking GMDS, CHO cells treated with
specific GMDS inhibitors, or even Tsta3-KO mice have a
near-complete deficiency of cellular fucosylation.9,10,36,37
However, these defects in de novo-pathway-dependent fu-
cosylation can be completely reversed if cells are provided
with exogenous L-fucose.9 Some positive results were seen
in several LAD-II cases, and thus it is quite likely that
L-fucose could be tested as a therapeutic option for this
disorder.
Surprisingly, the commonly-utilized model organism
Drosophila melanogaster lacks not only a protein ortholog
to human FUK, but also an ortholog to FPGT, suggesting
that the salvage pathwaymight not be critical for fly devel-
opment.38 Studies in zebrafish show that salvage-pathway
enzymes are provided maternally; detectable transcripts
for FUK and FPGT are not detected until the 16–32 cell
stage, prior to the beginning of zygotic transcription.39
In contrast, enzymes encoding for the de novo pathway
are present throughout development.39
Although next-generation sequencing will certainly
identify more potential FUK-CDG cases, confirming their
diagnosis might be difficult unless reliable biomarkers
can be discovered. Until then, fibroblast cell lines will be
needed to directly assay FUK activity.
Here we show that FUK, a core component of the fucose-
salvage pathway, causes a congenital glycosylation disor-
der characterized by defective fucose salvage.Supplemental Data
Supplemental Data include two figures and can be found with this
article online at https://doi.org/10.1016/j.ajhg.2018.10.021.The American JourConsortia
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